ID   JEKO-1 R
AC   CVCL_HF56
DR   Wikidata; Q54898570
RX   PubMed=26439697;
CC   Population: Korean.
CC   Doubling time: 20.5 +- 1.2 hours (PubMed=26439697).
CC   Selected for resistance to: ChEBI; CHEBI:91385; PF-00477736.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro58Glnfs*65 (c.173delC); ClinVar=VCV001394451; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C4337; Mantle cell lymphoma
DI   ORDO; Orphanet_52416; Mantle cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1865 ! JeKo-1
SX   Female
AG   78Y
CA   Cancer cell line
DT   Created: 01-12-16; Last updated: 29-06-23; Version: 13
//
RX   PubMed=26439697; DOI=10.18632/oncotarget.5954;
RA   Restelli V., Chila R., Lupi M., Rinaldi A., Kwee I., Bertoni F.,
RA   Damia G., Carrassa L.;
RT   "Characterization of a mantle cell lymphoma cell line resistant to the
RT   Chk1 inhibitor PF-00477736.";
RL   Oncotarget 6:37229-37240(2015).
//